Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hikmet Al-Hiti

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Frontiers in Cardiovascular Medicine|June 20, 2022
Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma PotassiumLuca Monzo, Adrian Reichenbach, Hikmet Al-Hiti, et al.
International Journal of Cardiology|October 13, 2012
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control studyAdrian Reichenbach, Hikmet Al-Hiti, Ivan Malek, et al.
Journal of the American College of Cardiology|August 8, 2009
Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafilVojtech Melenovsky, Hikmet Al-Hiti, Ludmila Kazdova, et al.
The European Respiratory Journal|February 14, 2018
Macitentan in pulmonary hypertension due to left ventricular dysfunctionJean-Luc Vachiéry, Marion Delcroix, Hikmet Al-Hiti, et al.
Journal of Cardiac Failure|November 24, 2020
Acute Unloading Effects of Sildenafil Enhance Right Ventricular-Pulmonary Artery Coupling in Heart FailureLuca Monzo, Adrian Reichenbach, Hikmet Al-Hiti, et al.
International Journal of Cardiology|February 15, 2014
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patientsGérald Simonneau, Nazzareno Galiè, Pavel Jansa, et al.
Circulation. Heart Failure|September 23, 2025
Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart FailureVojtech Melenovsky, Petr Jarolim, Eva Kutilkova, et al.
BMC Pulmonary Medicine|March 18, 2014
Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registryPavel Jansa, Jiri Jarkovsky, Hikmet Al-Hiti, et al.
The European Respiratory Journal|June 27, 2015
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertensionVallerie McLaughlin, Richard N Channick, Hossein-Ardeschir Ghofrani, et al.
Pulmonary Circulation|August 18, 2025
Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE StudiesJames R Klinger, Hikmet Al-Hiti, Sung-A Chang, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Frontiers in Cardiovascular Medicine|June 20, 2022
Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma PotassiumLuca Monzo, Adrian Reichenbach, Hikmet Al-Hiti, et al.
International Journal of Cardiology|October 13, 2012
The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control studyAdrian Reichenbach, Hikmet Al-Hiti, Ivan Malek, et al.
Journal of the American College of Cardiology|August 8, 2009
Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafilVojtech Melenovsky, Hikmet Al-Hiti, Ludmila Kazdova, et al.
The European Respiratory Journal|February 14, 2018
Macitentan in pulmonary hypertension due to left ventricular dysfunctionJean-Luc Vachiéry, Marion Delcroix, Hikmet Al-Hiti, et al.
Journal of Cardiac Failure|November 24, 2020
Acute Unloading Effects of Sildenafil Enhance Right Ventricular-Pulmonary Artery Coupling in Heart FailureLuca Monzo, Adrian Reichenbach, Hikmet Al-Hiti, et al.
International Journal of Cardiology|February 15, 2014
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patientsGérald Simonneau, Nazzareno Galiè, Pavel Jansa, et al.
Circulation. Heart Failure|September 23, 2025
Transpulmonary Proteome Gradients Identify Pathways Involved in Pulmonary Vascular Disease Due To Heart FailureVojtech Melenovsky, Petr Jarolim, Eva Kutilkova, et al.
BMC Pulmonary Medicine|March 18, 2014
Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registryPavel Jansa, Jiri Jarkovsky, Hikmet Al-Hiti, et al.
The European Respiratory Journal|June 27, 2015
Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertensionVallerie McLaughlin, Richard N Channick, Hossein-Ardeschir Ghofrani, et al.
Pulmonary Circulation|August 18, 2025
Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE StudiesJames R Klinger, Hikmet Al-Hiti, Sung-A Chang, et al.
Pageof 2